About ONCOHOST
ONCOHOST is a company based in Binyamina-giv'at Ada (Israel) founded in 2017 by Yuval Shaked and Ofer Sharon. ONCOHOST has raised $43 million across 4 funding rounds from investors including OurCrowd, European Commission and Menorah Mivathim. ONCOHOST offers products and services including PROphet Platform and PROphetNSCLC Test. ONCOHOST operates in a competitive market with competitors including Oncimmune, Biodesix, OncoCyte, GenomOncology and Broncus, among others.
- Headquarter Binyamina-giv'at Ada, Israel
- Founders Yuval Shaked, Ofer Sharon
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$43 M (USD)
in 4 rounds
-
Latest Funding Round
$2.8 M (USD), Grant
May 15, 2025
-
Investors
OurCrowd
& 5 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of ONCOHOST
ONCOHOST offers a comprehensive portfolio of products and services, including PROphet Platform and PROphetNSCLC Test.
AI platform for predicting benefits of cancer therapies using proteomics
Specific test for non-small cell lung cancer treatment predictions
People of ONCOHOST
Unlock access to complete
Unlock access to complete
Funding Insights of ONCOHOST
ONCOHOST has successfully raised a total of $43M across 4 strategic funding rounds. The most recent funding activity was a Grant round of $2.8 million completed in May 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in ONCOHOST
ONCOHOST has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include OurCrowd, European Commission and Menorah Mivathim.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Investment banking and advisory services are provided by Leumi Partners.
|
Locked | Locked | Locked | |
|
Pension and provident funds are managed by Israeli non-banking institution.
|
Locked | Locked | Locked |
Investor details for ONCOHOST
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by ONCOHOST
Investment portfolio details for ONCOHOST
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - ONCOHOST
Detailed financials for ONCOHOST
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Oncohost Comparisons
Peer comparison for ONCOHOST
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of ONCOHOST
ONCOHOST operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Oncimmune, Biodesix, OncoCyte, GenomOncology and Broncus, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Diagnostics and risk assessment solutions for lung cancer are developed.
|
|
| Locked | Locked | Locked |
Cancer detection diagnostics assays are developed and offered.
|
|
| Locked | Locked | Locked |
Non-invasive diagnostic test solutions for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Genomic data is transformed into actionable insights for precision medicine.
|
|
| Locked | Locked | Locked |
Minimally invasive technologies for lung disease treatment are developed.
|
Detailed competitors of ONCOHOST
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Oncohost
Complete news archive for ONCOHOST
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ONCOHOST
ONCOHOST was founded in 2017 and raised its 1st funding round 3 years after it was founded.
ONCOHOST is headquartered in Binyamina-giv'at Ada, Israel. It is registered at Binyamina-giv'at Ada, Haifa District, Israel.
Ofer Sharon is the current CEO of ONCOHOST. They have also founded this company.
ONCOHOST is a funded company, having raised a total of $43M across 4 funding rounds to date.
ONCOHOST was founded in 2017 as a provider of AI-based solutions in the oncology sector. Proteomic changes in blood samples are analyzed to evaluate patient responses to cancer therapies. Treatment strategies are recommended to enhance therapy effectiveness. Consultancy services are delivered to patients, oncologists, nurses, and pharmaceutical companies. The PROphet bioinformatics tool is employed to detect proteomic patterns associated with therapy outcomes.
ONCOHOST's top competitors include Biodesix, OncoCyte and GenomOncology.
ONCOHOST offers PROphet Platform and PROphetNSCLC Test.
ONCOHOST has 6 investors. Key investors include OurCrowd, European Commission, Menorah Mivathim, ALIVE, and Leumi Partners.